earnings
confidence high
sentiment neutral
materiality 0.80
Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance
INCYTE CORP
2022-FY EPS reported
$1.52
revenue$3,394,635,000
- FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.
- Jakafi net rev Q4 $647M (+9%), FY $2.41B (+13%); 2023 guidance range $2.53–2.63B.
- Opzelura net rev Q4 $61M, FY $129M driven by atopic dermatitis and vitiligo launch; patent extended to 2040.
- GAAP net income $341M (vs $949M in 2021, which included a large tax benefit); cash & securities $3.2B.
- 2023 guidance: Jakafi $2.53–2.63B; R&D $1.61–1.65B GAAP; SG&A $1.05–1.15B GAAP.